Form 8-K - Current report:
SEC Accession No. 0001479290-24-000118
Filing Date
2024-08-28
Accepted
2024-08-27 17:31:08
Documents
14
Period of Report
2024-08-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20240827.htm   iXBRL 8-K 33438
2 EX-99.1 rvncex991_waivertoagreemen.htm EX-99.1 9605
  Complete submission text file 0001479290-24-000118.txt   171625

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240827.xsd EX-101.SCH 1939
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240827_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240827_pre.xml EX-101.PRE 12544
17 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240827_htm.xml XML 2822
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241250192
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)